Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles.
-
Weiss GJ. Cost-effectiveness of capivasertib plus abiraterone for PTEN-deficient metastatic hormone-sensitive prostate cancer in the United States. PLoS One. 2026; 21(10):e0353373.
-
Zhang S, Li M, Liu M, Patten ND, Labaf M, Jeong J, Sun H, Lourie J, Zou K, Patalano S, Mulhearn MJ, Macoska JA, Gao S, Andreotti R, Pennuto M, Han D, Balk SP, Cai C. Minimal-length CAG repeats in AR define a hyperactive AR-LSD1 axis driving metabolic reprogramming in prostate cancer. Proc Natl Acad Sci U S A. 2026 Sep 15; 123(37):e2534152123.
-
Tak HJ, Shih YT, Grimm BL, Goldsweig AM, Lee MS, Horner RD. Association of cancer characteristics with disability status and timing of onset among working-age cancer survivors. JNCI Cancer Spectr. 2026 Sep 03; 10(5).
-
Griffin JN, Danowski ME, Gerety HL, Lafferty K, Clayman ML, Antwi AA, Bertero MG, Brunette CA, Gillespie C, Guentert L, Lennon NJ, Martin J, Patel LS, Vassy JL. Development and pilot testing of a prostate cancer polygenic risk report. BMC Med Genomics. 2026 07 30; 19(1).
-
Chernysheva D, Di Bello F, Avesani G, Baboudjian M, Barret E, Breda A, Briganti A, Budäus L, Comperat E, Diamand R, De Meerleer G, De Rooij M, Giganti F, Giannarini G, Goffin K, Hernández Mancera J, Jereczek-Fossa BA, Kasivisvanathan V, Kesch C, Klotz L, Lughezzani G, Malavaud B, Moore C, Murphy D, Oprea-Lager D, Padhani A, Panebianco V, Ploussard G, Rannikko A, Raspollini MR, Rembak-Szynkiewicz J, Schoots I, Spohn SK, Stabile A, Tilki D, Tree A, Walz J, MacLennan S, Sanguedolce F. ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy. Eur Urol. 2026 Sep; 90(3):212-224.
-
Fanti S, Turco F, Tombal B, Walz J, Hofman MS, Hadaschik B, Emmett L, Tilki D, Pecoraro G, Salfi G, Attard G, Beltran H, Bjartell A, Briganti A, Burger IA, Castro E, Cerci JJ, Chiti A, Cooperberg M, Fizazi K, Fossati N, Gafita A, Gallina A, Goffin K, Horvath LG, Hugosson J, Iagaru A, James ND, Kasivisvanathan V, Koh DM, Kristiansen G, Kumar R, Lecouvet F, Loeb S, McKay RR, Morris MJ, Murphy DG, Murthy V, Naoun N, Oprea-Lager DE, Ost P, O'Sullivan J, Padhani AR, Palapattu G, Paone G, Petralia G, Roobol MJ, Sartor OA, Sathekge M, Schuster DM, Seibert TM, Spratt DE, Tempany C, Tunariu N, Vargas HA, Vogl UM, Wyatt AW, Zilli T, Lin HM, Omlin A, Gillessen S, Herrmann K. Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics. Eur Urol. 2026 Oct; 90(4):347-376.
-
Buller DM, Dubovic V, Martin WE, Rosenfeld B, Sherman A, Faust WC, Ginzburg S, Wagner JR, Correa AF, Pinto K, Albertsen PC, Kutikov A, Ristau BT. Multi-Institutional Assessment of Performance Metrics for MRI-Targeted Transperineal Prostate Biopsy. J Urol. 2026 Oct; 216(4):511-517.
-
Dong Y, Liu M, Gao R, Li M, Zhai J, Cai C, Gao S. Identification of targets of clinical FOXA1 mutants involved in EMT and immune suppression in prostate cancer. Commun Biol. 2026 Jun 23; 9(1).
-
Xiang JC, Xia ZY, Sun JX, Ye GC, Wang Y, Yang J, Wang SG, Xia QD. First-in-human single-cell and TCR atlas reveals peripheral immune remodeling before and after irreversible electroporation in prostate cancer. J Immunother Cancer. 2026 May 13; 14(5).
-
Xia QD, Xu MY, Zhu XH, Yang J, Wang SG. PSMA PET/MRI-US Fusion-Guided Irreversible Electroporation for Focal Therapy of Prostate Cancer. Clin Nucl Med. 2026 Aug 01; 51(8):661-663.